Figure 1

Trough (Predose) Plasma Concentrations (μg/mL) of (-)-Halofenic Acid in Healthy Subjects Following Daily Oral Administration of 400 mg Arhalofenate for 30 Days




Figure 2

Mean ± SD (-)-Halofenic Acid Plasma Concentrations Following Daily Oral Administration of 400 mg Arhalofenate to Healthy Subjects




Figure 3



Time (days)
Serum Uric Acid
% Change from Baseline
20
10
0
-10
-20
-30
-40
-50
0
3
5
7
9
14
21
Treatment
Follow up
Placebo
400 mg Arhalofenate
600 mg Arhalofenate
600 mg Arhalofenate EC
800 mg Arhalofenate EC
1000 mg Arhalofenate EC
* EC = enteric coated

Figure 4



IL-1 β mRNA
Mean Fold Change vs LPS
1.5
1.0
0.5
0.0
** (p<0.01)
LPS
75 uM (-) halofenic acid
150 uM (-) halofenic acid

Figure 5



Secreted IL-1β
Mean FC vs. LPS
1.25
1.00
0.75
0.50
0.25
0.00
***
***
LPS
75
150
Arhalofenate (μM)

Figure 6




Mean hs-CRP Change (mg/L)
0
1
2
3
4
5
6
7
8
Day 1 (Baseline)
Day 8 (glyburide 6 mg)
Day 22 (arhalofenate 600 mg+glyburide 6 mg)

Figure 7


20
10
0
-10
-20
-30
-40
Change in hs-CRP from Day 1 (%)
Day 8 (glyburide 6 mg)
Day 22 (arhalofenate 600 mg+glyburide 6 mg)